UNITAID reduces pediatric HIV/AIDS drug price 40%

7 October 2007

The international drug purchasing facility UNITAID has claimed its first year to be a success, arguing that it has reduced HIV/AIDS therapies for children by "almost 40%." In addition, second-line antiretroviral drugs have been purchased at discounts of between 25%-50%. In collaboration with the US Clinton Foundation, UNITAID says it has delivered 30,000 pediatric treatments and believes it is on course to achieve drug coverage for 100,000 children by the end of the current year.

To date, the Geneva, Switzerland-headquartered agency has delivered ARVs in four African countries: Botswana, Cameroon, Uganda and Zambia.

Operating in conjunction with the World Health Organization and UNICEF, UNITAID has also bought 1.3 million doses of antimalarial artemisinin-based combination therapies for distribution in Burundi and Liberia. Eight further countries are also being supported by the agency's ACT effort, in cooperation with the Global Fund to Fight AIDS, Tuberculosis and Malaria, as well as UNICEF. Deliveries to these countries are due to begin during October.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight